In Vitro Evaluation of a Targeted and Sustained Release System for Retinoblastoma Cells Using Doxorubicin as a Model Drug
Open accessAbstract
PURPOSE: The objective of this study was to develop a novel folate receptor-targeted drug delivery system for retinoblastoma cells using doxorubicin (DOX) as a model drug. METHODS: Biodegradable DOX-loaded poly(d,l-lactide-co-glycolide)-poly(ethylene glycol)-folate (PLGA-PEG-FOL) micelles (DOXM) were prepared with various solvents (dimethylsulfoxide, acetone, and dimethylformamide). The effects of solvents on entrapment efficiency, particle size, and polydispersity were examined. The effects of thermosensitive gel structure on the release of DOX from the DOXM were also studied. Qualitative and quantitative uptake studies of DOX and DOXM were carried out in Y-79 cell line. Cytotoxicity studies of DOXM were performed on Y-79 cells. RESULTS: Based on size, polydispersity, and entrapment efficiency, dimethylformamide was found to be the most suitable solvent for the preparation of DOXM. Dispersion of DOXM in PLGA-PEG-PLGA gel sustained drug release for a period of 2 weeks. Uptake of DOX was ∼4 times higher with DOXM than DOX in Y-79 cells overexpressing folate receptors. This was further confirmed from the quantitative uptake studies. DOXM exhibited higher cytotoxicity in Y-79 cells when compared with pure DOX. CONCLUSION: These polymeric micellar systems suspended in thermosensitive gels may provide sustained and targeted delivery of anticancer agents to retinoblastoma cells following intravitreal administration.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
DOXM exhibited approximately a 4-fold higher uptake efficiency compared with free DOX in folate receptor-overexpressing Y-79 cells.
“DOXM exhibited approximately a 4-fold higher uptake efficiency compared with free DOX in folate receptor-overexpressing Y-79 cells.”
From From design to Deployment: The innovative role of nanomicelles in targeted ophthalmic therapeutics (2025) · cites this paper as [181]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Polymeric micelles—A new generation of colloidal drug carriers
Jones, M.-C., & Leroux, J.-C. (1999) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(99)00039-9 · Cited by 1,256 · see citing works
Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues.
Weitman, S. D., Lark, R. H., Coney, L. R., Fort, D. W., Frasca, V., Zurawski, V. R., & Kamen, B. A. (1992) · PubMed · Cited by 1,011 · see citing works
Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies
Kartner, N., Evernden-Porelle, D., Bradley, G., & Ling, V. W. T. (1985) · Nature · doi:10.1038/316820a0 · Cited by 908 · see citing works
Folate receptor targeted biodegradable polymeric doxorubicin micelles
Yoo, H. S., & Park, T. G. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.02.003 · Cited by 620 · see citing works
Recent Perspectives in Ocular Drug Delivery
Gaudana, R., Jwala, J., Boddu, S., & Mitra, A. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9694-0 · Cited by 600 · see citing works
Mortality From Second Tumors Among Long-Term Survivors of Retinoblastoma
Eng, C., Li, F. P., Abramson, D. H., Ellsworth, R. M., Wong, F. L., Goldman, M., Seddon, J. M., Tarbell, N. J., & Boice, J. D. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.14.1121 · Cited by 567 · see citing works
Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA–PEG block copolymer
Yoo, H. S., & Park, T. G. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00340-0 · Cited by 539 · see citing works
Chemotherapy Plus Local Treatment in the Management of Intraocular Retinoblastoma
Murphree, A. L. (1996) · Archives of Ophthalmology · doi:10.1001/archopht.1996.01100140548005 · Cited by 471 · see citing works
Chemotherapy With Focal Therapy Can Cure Intraocular Retinoblastoma Without Radiotherapy
Gallie, B. L. (1996) · Archives of Ophthalmology · doi:10.1001/archopht.1996.01100140521001 · Cited by 412 · see citing works
Chen, H., Kim, S., He, W., Wang, H., Low, P. S., Park, K., & Cheng, J.-X. (2008) · Langmuir · doi:10.1021/la703570m · Cited by 311 · see citing works
Qiao, M., Chen, D., Xi-chen, M., & Liu, Y. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.01.017 · Cited by 277 · see citing works
Liu, S. Q., Tong, Y. W., & Yang, Y.-Y. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2005.01.030 · Cited by 265 · see citing works
Park, E. K., Kim, S. Y., Lee, S. B., & Lee, Y. M. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.09.039 · Cited by 239 · see citing works
Novel approaches to retinal drug delivery
Janoria, K. G., Gunda, S., Boddu, S. H. S., & Mitra, A. K. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.371 · Cited by 213 · see citing works
Retinoblastoma: Review of Current Management
Chintagumpala, M., Chévez‐Barrios, P., Paysse, E. A., Plon, S. E., & Hurwitz, R. L. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1237 · Cited by 210 · see citing works
Aerts, I., Rouïc, L. L.-L., Gauthier‐Villars, M., Brisse, H. J., Doz, F., & Desjardins, L. (2006) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-1-31 · Cited by 195 · see citing works
Stability issues of polymeric micelles
Bae, Y. H., & Yin, H. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.06.015 · Cited by 182 · see citing works
Jeon, H.-J., Jeong, Y., Jang, M.-K., Park, Y.-H., & Nah, J. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00537-8 · Cited by 159 · see citing works
Beck, M. N., Balmer, A., Dessing, C., Pica, A., & Munier, F. L. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.15.2881 · Cited by 124 · see citing works
Selectivity of folate conjugated polymer micelles against different tumor cells
Zhao, H., & Yung, L. Y. L. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.07.040 · Cited by 122 · see citing works
Duvvuri, S., Janoria, K. G., & Mitra, A. K. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.09.002 · Cited by 110 · see citing works
Shiokawa, T., Hattori, Y., Kawano, K., Ohguchi, Y., Kawakami, H., Toma, K., & Maitani, Y. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1129 · Cited by 100 · see citing works
Historic Review of Retinoblastoma
Albert, D. M. (1987) · Ophthalmology · doi:10.1016/s0161-6420(87)33407-4 · Cited by 98 · see citing works
Roles of Multidrug Resistance Genes in Breast Cancer Chemoresistance
Kuo, M. T. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-74039-3_2 · Cited by 98 · see citing works
Aukunuru, J., Sunkara, G., Bandi, N., Thoreson, W. B., & Kompella, U. B. (2001) · Pharmaceutical Research · doi:10.1023/a:1011060705599 · Cited by 82 · see citing works
Management of Advanced Retinoblastoma
Honavar, S. G., & Singh, A. D. (2005) · Ophthalmology Clinics of North America · doi:10.1016/j.ohc.2004.09.001 · Cited by 81 · see citing works
Retinoblastoma. Review of the current status.
Bishop, J. O., & Madson, E. C. (1975) · PubMed · Cited by 76 · see citing works
Seven Cases of Trilateral Retinoblastoma
Pesin, S. R., & Shields, J. A. (1989) · American Journal of Ophthalmology · doi:10.1016/0002-9394(89)90209-2 · Cited by 67 · see citing works
Duvvuri, S., Janoria, K. G., Pal, D., & Mitra, A. K. (2007) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2006.132 · Cited by 64 · see citing works
Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines.
Hs, C., Canton, & Gallie, B. L. (1989) · PubMed · Cited by 62 · see citing works
Current treatment of retinoblastoma
Potter, P. D. (2002) · Current Opinion in Ophthalmology · doi:10.1097/00055735-200210000-00007 · Cited by 57 · see citing works
The Adverse Events of Chemotherapy for Retinoblastoma
Rizzuti, A. E. (2008) · Archives of Ophthalmology · doi:10.1001/archopht.126.6.862 · Cited by 52 · see citing works
Huang, W. Y., Prasad, P. D., Kekuda, R., Leibach, F. H., & Ganapathy, V. (1997) · PubMed · Cited by 41 · see citing works
Folic acid transport via high affinity carrier-mediated system in human retinoblastoma cells
Kansara, V. S., Paturi, D., Luo, S., Gaudana, R., & Mitra, A. K. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.12.008 · Cited by 30 · see citing works
Regulation of the multidrug resistance (MDR1) gene expression.
Chin, K., & Liu, B. (1995) · PubMed · Cited by 11 · see citing works
Phylactos, A. C., & UNGER, W. G. (1998) · Documenta Ophthalmologica · doi:10.1023/a:1001738931928 · Cited by 9 · see citing works
[Studies on multidrug resistance associated protein in retinoblastoma].
Li, B., Gao, R., Zhang, H., Li, L.-Q., Gao, F., & Ren, R. (2009) · PubMed · Cited by 8 · see citing works
Roblot-Treupel, L., Poupon, M., Couvreur, P., & Puisieux, F. (1991) · PubMed · Cited by 7 · see citing works
Retinoblastoma. Can we do more?
Codina, J. S. D. T. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0245-8 · Cited by 1 · see citing works
Henkes, H. E., Henkes, H. E., & Oosterhuis, J. A. (1977) · Documenta Ophthalmologica · doi:10.1007/bf01569203 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406 · see citing works
Self-citationNanomedicines for back of the eye drug delivery, gene delivery, and imaging
Kompella, U. B., Amrite, A. C., Pacha-Ravi, R., & Durazo, S. A. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.04.001 · Cited by 262 · see citing works
Thermosensitive Polymeric Micelles for Targeted Drug Delivery
Talelli, M., & Hennink, W. E. (2011) · Nanomedicine · doi:10.2217/nnm.11.91 · Cited by 119 · see citing works
Singh, R., Kesharwani, P., Mehra, N. K., Singh, S. K., Banerjee, S., & Jain, N. K. (2015) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2015.1019355 · Cited by 106 · see citing works
Nano-ophthalmology: Applications and considerations
Kamaleddin, M. A. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.02.007 · Cited by 105 · see citing works
Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancer.
Vangara, K. K., Liu, J. L., & Palakurthi, S. (2013) · PubMed · Cited by 96 · see citing works
Polyamide/Poly(Amino Acid) Polymers for Drug Delivery
Boddu, S. H. S., Bhagav, P., Karla, P. K., Jacob, S., Adatiya, M. D., Dhameliya, T. M., Ranch, K. M., & Tiwari, A. K. (2021) · Journal of Functional Biomaterials · doi:10.3390/jfb12040058 · Cited by 73 · see citing works
Green Light‐Triggered Intraocular Drug Release for Intravenous Chemotherapy of Retinoblastoma
Long, K., Yang, Y., Lv, W., Jiang, K., Li, Y., Lo, A., Lam, W., Zhan, C., & Wang, W. (2021) · Advanced Science · doi:10.1002/advs.202101754 · Cited by 60 · see citing works
Therapeutic Options for Retinoblastoma
Mendoza, P. R., & Grossniklaus, H. E. (2016) · Cancer Control · doi:10.1177/107327481602300203 · Cited by 64 · see citing works
Ocular Drug Delivery: A Special Focus on the Thermosensitive Approach
Sapino, S., Chirio, D., Peira, E., Rubio, E. A., Brunella, V., Jadhav, S. A., Chindamo, G., & Gallarate, M. (2019) · Nanomaterials · doi:10.3390/nano9060884 · Cited by 64 · see citing works
Evolution of Nanotechnology in Delivering Drugs to Eyes, Skin and Wounds via Topical Route
Raghu, P. K., Bansal, K. K., Thakor, P., Bhavana, V., Madan, J., Rosenholm, J. M., & Mehra, N. K. (2020) · Pharmaceuticals · doi:10.3390/ph13080167 · Cited by 56 · see citing works
Vu-Quang, H., Vinding, M. S., Nielsen, T., Ullisch, M. G., Nielsen, N. C., & Kjems, J. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.04.010 · Cited by 48 · see citing works
Folate decorated nanomicelles loaded with a potent curcumin analogue for targeting retinoblastoma
Alsaab, H., Alzhrani, R., Kesharwani, P., Sau, S., Boddu, S., & Iyer, A. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020015 · Cited by 46 · see citing works
Boddu, S. H. S., & Vaishya, R. D. (2012) · Medicinal Chemistry · doi:10.4172/2161-0444.1000117 · Cited by 41 · see citing works
Management of retinoblastoma: opportunities and challenges
Bhavsar, D. V., Krishnakumar, S., Sethuraman, S., & Krishnan, U. M. (2015) · Drug Delivery · doi:10.3109/10717544.2015.1016193 · Cited by 35 · see citing works
Onugwu, A. L., Ugorji, O. L., Ufondu, C. A., Ihim, S. A., Echezona, A. C., Nwagwu, C. S., Onugwu, S. O., Uzondu, S. W., Agbo, C. P., Ogbonna, J. D., et al. (2023) · Nanoscale Advances · doi:10.1039/d3na00462g · Cited by 33 · see citing works
Intravitreal galactose conjugated polymeric nanoparticles of etoposide for retinoblastoma
Godse, R. D., Rathod, M., De, A., & Shinde, U. A. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.102259 · Cited by 28 · see citing works
Wade, S. J., Amanda, Z., Foroughi, J., Talebian, S., Aghmesheh, M., Moulton, S. E., & Vine, K. L. (2017) · Pancreatology · doi:10.1016/j.pan.2017.06.001 · Cited by 28 · see citing works
Lu, Y., Gao, X., Cao, M., Wu, B., Su, L., Chen, P., Miao, J., Wang, S., Xia, R., & Qian, J. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.110830 · Cited by 26 · see citing works
Advances in biomaterials for the treatment of retinoblastoma
Farhat, W., Yeung, V., Ross, A., Kahale, F., Boychev, N., Kuang, L., Chen, L., & Ciolino, J. B. (2022) · Biomaterials Science · doi:10.1039/d2bm01005d · Cited by 26 · see citing works
Jwala, J., Vadlapatla, R. K., Vadlapudi, A. D., Boddu, S. H. S., Pal, D., & Mitra, A. K. (2012) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2011.0155 · Cited by 26 · see citing works
Nanotechnology-Based Approaches for Ophthalmology Applications
Sharaf, M. G., Çetinel, S., Heckler, L. V., Damji, K. F., Unsworth, L. D., & Montemagno, C. D. (2014) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000059 · Cited by 25 · see citing works
The Role of Nano-ophthalmology in Treating Dry Eye Disease
Natesan, S., Boddu, S. H. S., Krishnaswami, V., & Shahwan, M. J. (2020) · Pharmaceutical Nanotechnology · doi:10.2174/2211738508666200628034227 · Cited by 19 · see citing works
Pareek, A., Kumar, D., Pareek, A., Gupta, M. M., Jeandet, P., Ratan, Y., Jain, V., Kamal, M. A., Saboor, M., Ashraf, G. M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32844 · Cited by 19 · see citing works
Polymeric Nanoparticulate Systems: A Potential Approach for Ocular Drug Delivery
Godse, R. D., Singh, K., Shrivastava, A., & Shinde, U. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-29346-2_16 · Cited by 17 · see citing works
Lin, S., Deng, F., Huang, P., Li, L., Wang, L., Li, Q. F., Chen, L., Chen, H., & Nan, K. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb00736d · Cited by 15 · see citing works
Utility of transporter/receptor(s) in drug delivery to the eye
Boddu, S. H., & Nesamony, J. (2013) · World Journal of Pharmacology · doi:10.5497/wjp.v2.i1.1 · Cited by 16 · see citing works
Alhakamy, N. A. (2021) · AAPS PharmSciTech · doi:10.1208/s12249-021-02111-w · Cited by 11 · see citing works
RetractedAnsari, M., Gupta, C., Kulkarni, Y. A., & Singh, K. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125235 · Cited by 10 · see citing works
Ansari, M., Kulkarni, Y. A., & Singh, K. (2023) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2023045298 · Cited by 10 · see citing works
Hatem, S., Mohammed, D., & Ezzat, N. (2024) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-024-00587-4 · Cited by 8 · see citing works
From design to Deployment: The innovative role of nanomicelles in targeted ophthalmic therapeutics
Sun, M., Wang, J., Fan, W., Wang, K., Wang, Y., Zhang, J., Ding, S., Zhang, C., Feng, Z., Wang, Y.-G., et al. (2025) · Materials today. Bio · doi:10.1016/j.mtbio.2025.102537 · Cited by 7 · see citing works
“Dispersion of DOXM in PLGA-PEG-PLGA gel facilitated the sustained drug release over a period of 2 weeks [181].”
Klose, A., Gounani, Z., Ijäs, H., Lajunen, T., Linko, V., & Laaksonen, T. (2024) · Nanoscale · doi:10.1039/d4nr01995d · Cited by 6 · see citing works
Hatamie, S., Shih, P., Chen, B., & Hatami, N. (2025) · Polymers for Advanced Technologies · doi:10.1002/pat.70094 · Cited by 6 · see citing works
Wu, J., Tian, X., Yin, Y., He, M. X., Cai, W., He, G., Xu, W., Dai, Y., Mai, J., Gan, M., et al. (2019) · European Polymer Journal · doi:10.1016/j.eurpolymj.2019.109350 · Cited by 6 · see citing works
Nanomedicine-Based Treatments for Rare and Aggressive Ocular Cancers: Advances in Drug Delivery
Kapoor, D. U., Patel, G. K., & Prajapati, B. G. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01330-8 · Cited by 6 · see citing works
Shinde, U. A., De, A., Godse, R. D., Rathod, M., Thorat, R. A., Sharma, N., Ansari, M., & Singh, K. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105333 · Cited by 5 · see citing works
Boddu, S. H. S., Tukaramrao, D. B., Al-Tabakha, M. M., Ashames, A., Neupane, R., Babu, R. J., Renukuntla, J., & Tiwari, A. K. (2020) · Pharmaceuticals · doi:10.3390/ph13110353 · Cited by 5 · see citing works
Ranganath, S. H., Thanuja, M. Y., Anupama, C., & Manjunatha, T. D. (2020) · Gels horizons: from science to smart materials · doi:10.1007/978-981-15-7998-1_6 · Cited by 5 · see citing works
Ansari, M., Kulkarni, Y. A., & Singh, K. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106605 · Cited by 3 · see citing works
The Contribution of Nanomedicine in Ocular Oncology
Spyratou, E., Margarita, T., Droulias, A., Zachou, M.-E., & EFSTATHOPOULOS, E. P. (2025) · Cancers · doi:10.3390/cancers17071186 · Cited by 3 · see citing works
In vitro triple culture model of retinoblastoma for pre‐clinical investigations
Jahagirdar, D., Jain, R. D., & Dandekar, P. P. (2023) · Biotechnology Journal · doi:10.1002/biot.202200518 · Cited by 3 · see citing works
Nanomedicine-Based Delivery to the Posterior Segment of the Eye: Brighter Tomorrow
Jalil, A., Kanwar, R. K., Pathak, Y. V., Mohammedawi, M. A., & Kanwar, J. R. (2018) · Springer eBooks · doi:10.1007/978-3-319-95807-1_11 · Cited by 3 · see citing works
Receptor-Targeted Prodrug Approach for Retina and Posterior Segment Disease
Mehta, T. A., Patel, V. F., & Sharma, O. P. (2018) · Springer eBooks · doi:10.1007/978-3-319-95807-1_21 · Cited by 2 · see citing works
Tamboli, V. (2012) · Cited by 1 · see citing works
Sobre Ton Sirera i la realitat
Vallverdú, J. (1996) · Ressò de Ponent: revista de l'Ateneu Popular de Ponent
- Authors
- Boddu, S. H. S., Jwala, J., Chowdhury, M. R., & Mitra, A. K.
- Affiliations
- University of Missouri–Kansas City (US)
- Corresponding author
- Mitra, Ashim K.
- Venue
- Journal of Ocular Pharmacology and Therapeutics
- Publisher
- SAGE Publications
- Published
- 2010-10
- Volume
- 26
- Issue
- 5
- Pages
- 459-468
- ISSN
- 1080-7683 (ISSN-L)
- 1557-7732
- PMC
- PMC2956377
- OpenAlex
- W2035506230
- Cited by
- 46
- References
- 40
- Citations by year
- 2025: 6 · 2024: 4 · 2023: 3 · 2022: 1 · 2021: 3 · 2020: 6 · 2019: 2 · 2018: 2 · 2017: 3 · 2016: 3 · 2015: 3 · 2014: 1 · 2013: 3 · 2012: 3
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Ocular Pharmacology and Therapeutics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Directorate for Biological Sciences
- National Eye Institute (R01EY009171, R01EY10659-12, R01EY09171-16, R01EY010659)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Keywords
- retinoblastoma, doxorubicin, folate receptor targeting, polymeric micelles, thermosensitive hydrogel, sustained drug release, targeted drug delivery, Y79 cells, intravitreal administration, cytotoxicity
- MeSH terms
- Polylactic Acid-Polyglycolic Acid Copolymer, Antibiotics, Antineoplastic, Cell Survival, Delayed-Action Preparations, Doxorubicin, Drug Carriers, Folic Acid, Gels, Humans, Micelles, Particle Size, Polyethylene Glycols, Polyglycolic Acid, Polymers, Retinoblastoma, Solvents, Drug Delivery Systems, Lactic Acid, Cell Line, Tumor, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
